Drug updated on 9/4/2024
Dosage Form | Injection (intramuscular; 0.5 mL) |
Drug Class | Vaccines |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for active immunization against diphtheria, tetanus, and pertussis as a 5-dose series in infants and children aged 6 weeks through 6 years (prior to the seventh birthday).
Latest News
Summary
- Infanrix (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) is indicated for active immunization against diphtheria, tetanus, and pertussis as a 5-dose series in infants and children aged 6 weeks through 6 years (prior to the seventh birthday).
- This summary is based on the review of three systematic review(s)/meta-analysis(es). [1-3]
- Infants of Tdap-immunized mothers exhibited significantly lower IgG levels against pertussis antigens post-primary immunization and reduced seroprotection rates for diphtheria (90% vs. 98%) and specific Streptococcus pneumoniae serotypes but higher seroprotection against Haemophilus influenzae type b compared to infants of unimmunized mothers.
- The 5-component pertussis vaccines, including Infanrix, were shown to be more effective than the 1-component vaccine in generating an immune response in adolescents and adults after booster doses, despite containing a lower dose of antigen.
- Following booster immunization, infants of Tdap-immunized mothers maintained very high seroprotection rates for diphtheria and tetanus (99%).
- The evidence highlights different immunogenic responses in infants of Tdap-immunized mothers compared to those of unimmunized mothers, with a focus on adolescents and adults receiving booster doses of 5-component vaccines.
- The reviewed studies highlight specific population types and subgroups including infants of Tdap-immunized mothers, adolescents, and adults, with clinically relevant findings such as lower antibody levels and different seroprotection rates in infants of Tdap-immunized mothers, and the efficacy of 5-component vaccines as boosters in adolescents and adults.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Infanrix (diphtheria and tetanus toxoids and acellular pertussis vaccine) Prescribing Information. | 2023 | GlaxoSmithKline, Durham, NC |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Guillain Barré syndrome after combined diphtheria, tetanus, and acellular pertussis (DTaP) vaccine: a rare pediatric case report and review of literature. | 2023 | Human Vaccines and Immunotherapeutics |
The effect of tetanus-diphtheria-acellular-pertussis immunization during pregnancy on infant antibody responses: individual-participant data meta-analysis. | 2021 | Frontiers in Immunology |
Immunogenicity and antibody persistence of diphteria-tetanus-acellular pertussis vaccination in adolescents and adults: a systematic review of the literature showed different responses to the available vaccines. | 2021 | Journal of Preventive Medicine and Hygiene |